Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVS · Entity 4839 | Director | June 12, 2025 | June 16, 2025 |
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director | June 16, 2026 | June 18, 2026 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director | June 25, 2026 | June 29, 2026 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
| Zai Lab LtdZLAB · Entity 4271 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvus Pharmaceuticals, Inc.
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2035-06-12 | Direct | 15,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 15,000 · Balance 15,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
IDEAYA Biosciences, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16 | Direct | 20,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.
Tarsus Pharmaceuticals, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.34 · Expires 2036-06-24 | Direct | 3,837 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 3,837 · Balance 3,837 F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,417 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 2,417 · Balance 2,417 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Zai Lab Ltd
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 56,904 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 22,371 · Balance 56,904 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Audentes Therapeutics, Inc.
Report date January 15, 2020 · Filed January 15, 2020
Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2025-12-26 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-15 · Disposition to issuer · Disposed 33,635 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.03 · Expires 2026-08-24 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.15 · Expires 2027-10-08 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.65 · Expires 2028-06-08 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-15 · Disposition to issuer · Disposed 16,200 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01.
Global Blood Therapeutics, Inc.
Report date October 05, 2022 · Filed October 06, 2022
Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 1
1 source rowRow 1 · 2022-10-05 · Disposition to issuer · Disposed 6,637 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.21 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-05 · Disposition to issuer · Disposed 30,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.45 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:31 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001662426-26-000006 · wk-form4_1782765098.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,417 Underlying: Common Stock · 2,417 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:31 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 3,837 | $0.00 Strike: $64.34 | $0.00 |
DisclosureSEC source: 0001662426-26-000006 · wk-form4_1782765098.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,837 Underlying: Common Stock · 3,837 shares Expires 2036-06-24 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:08 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 22,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003030 · form4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,904 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:32 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $30.57 | $0.00 |
DisclosureSEC source: 0001610717-26-000261 · form4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 2,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001662426-26-000004 · wk-form4_1781640402.xml · derivative · entry 3 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F4 · derivative.expiration_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 2,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662426-26-000004 · wk-form4_1781640402.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:24 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 17,084 | $0.00 Strike: $34.35 | $0.00 |
DisclosureSEC source: 0001662426-26-000002 · form4-05262026_080514.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,084 Underlying: Class A Common Stock · 17,084 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001662426-25-000005 · wk-form4_1758053184.xml · derivative · entry 3 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vested in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs vested in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 1,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662426-25-000005 · wk-form4_1758053184.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:55 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.78 | $0.00 |
DisclosureSEC source: 0001610717-25-000262 · form4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:11 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 10,831 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002218 · form4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,533 F1 · security: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2026, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000090 · wk-form4_1750104245.xml · derivative · entry 5 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F5 · derivative.expiration_date: RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 3,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-25-000090 · wk-form4_1750104245.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000090 · wk-form4_1750104245.xml · derivative · entry 4 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,954 Underlying: Common Stock · 2,954 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F4 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 4,540 | $0.00 Strike: $40.95 | $0.00 |
DisclosureSEC source: 0001819790-25-000090 · wk-form4_1750104245.xml · derivative · entry 3 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,540 Underlying: Common Stock · 4,540 shares Expires 2035-06-11 F2 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:27 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001610717-25-000231 · form4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001415889-25-013412 · form4-05162025_080528.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Class A Common Stock · 14,000 shares Expires 2035-05-13 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:48 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleAmerican Depositary Shares | 23,799 | $30.05 | $715,086.17 |
DisclosureSEC source: 0000905148-25-001598 · form4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,702 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · price: Reflects a weighted average sale price of $30.0469 per share, at prices ranging from $30.01 to $30.18 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 21:27 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GiftCommon Stock | 6,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000115 · wk-form4_1727904418.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · ownership.direct: The Reporting Person transferred 6,016 shares of common stock to the Morrison-Minton Family 2004 Trust for no consideration. The Reporting Person is trustee of the Morrison-Minton Family 2004 Trust, and the Reporting Person and his spouse are the sole beneficiaries of the trust. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 21:52 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000113 · wk-form4_1726609924.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,334 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. F2 · derivative.expiration_date: The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 21:52 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000113 · wk-form4_1726609924.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 22:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000099 · wk-form4_1719354184.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 22:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 3,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000099 · wk-form4_1719354184.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:00 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 21,253 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001749 · form4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,501 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2 · shares: Represents restricted shares that vest in full on June 18, 2025, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000075 · wk-form4_1718400631.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $33.14 | $0.00 |
DisclosureSEC source: 0001819790-24-000075 · wk-form4_1718400631.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:44 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001610717-24-000342 · form4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:38 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 16,200 | $0.00 Strike: $36.55 | $0.00 |
DisclosureSEC source: 0001610717-24-000275 · form4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2034-05-30 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $42.69 | $0.00 |
DisclosureSEC source: 0001415889-24-013490 · form4-05172024_080541.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Class A Common Stock · 14,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 21:03 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001610717-23-000388 · form4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 20:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000075 · wk-form4_1695155145.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. F2 · derivative.expiration_date: The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 20:25 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-23-000075 · wk-form4_1695155145.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:17 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantAmerican Depositary Shares | 18,903 | $26.45 | $499,984.35 |
DisclosureSEC source: 0000950170-23-031116 · ownership.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,248 F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 21:45 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000052 · wk-form4_1687815920.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 21:45 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001819790-23-000052 · wk-form4_1687815920.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:59 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001610717-23-000186 · form4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:45 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 16,200 | $0.00 Strike: $25.40 | $0.00 |
DisclosureSEC source: 0001610717-23-000112 · form4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2033-06-06 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001209191-23-029031 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2033-05-09 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 20:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-026246 · wf-form4_166551982032663.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs will vest in three equal annual installments on September 15th of each of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in three equal annual installments on September 15th of each of 2023, 2024, and 2025, subject to the Reporting Person's continuous service. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 20:23 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantEmployee Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $17.21 | $0.00 |
DisclosureSEC source: 0001628280-22-026246 · wf-form4_166551982032663.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2032-10-05 F1 · derivative.exercise_date: The option shares vest in three equal annual installments beginning on October 6, 2023, subject to the Reporting Person's continuous service. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,600 | Not disclosed Strike: $22.30 | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 10 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,600 | Not disclosed Strike: $37.09 | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 9 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,247 | Not disclosed Strike: $64.75 | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 8 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,247 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $56.30 | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 7 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $42.25 | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 6 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $28.45 | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 5 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $18.85 | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 4 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $29.21 | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 3 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerRestricted Stock Units · Derivative | 3,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:20 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerCommon Stock | 6,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033163 · doc4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.